Fort Washington Investment Advisors Inc. OH raised its stake in Medpace Holdings Inc (NASDAQ:MEDP) by 59.1% during the 1st quarter, Holdings Channel reports. The firm owned 7,000 shares of the company’s stock after buying an additional 2,600 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Medpace were worth $413,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its holdings in shares of Medpace by 27.3% during the third quarter. JPMorgan Chase & Co. now owns 134,620 shares of the company’s stock worth $8,065,000 after purchasing an additional 28,849 shares during the last quarter. Bank of Montreal Can grew its holdings in shares of Medpace by 14.1% during the fourth quarter. Bank of Montreal Can now owns 36,029 shares of the company’s stock worth $1,907,000 after purchasing an additional 4,447 shares during the last quarter. New York State Teachers Retirement System grew its holdings in shares of Medpace by 1,028.7% during the fourth quarter. New York State Teachers Retirement System now owns 11,287 shares of the company’s stock worth $597,000 after purchasing an additional 10,287 shares during the last quarter. Arizona State Retirement System purchased a new position in shares of Medpace during the fourth quarter worth about $2,006,000. Finally, Oppenheimer Asset Management Inc. purchased a new position in shares of Medpace during the fourth quarter worth about $198,000. Hedge funds and other institutional investors own 76.70% of the company’s stock.

In other Medpace news, CFO Jesse J. Geiger sold 25,037 shares of Medpace stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $60.00, for a total value of $1,502,220.00. Following the sale, the chief financial officer now owns 25,037 shares of the company’s stock, valued at approximately $1,502,220. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Stephen P. Ewald sold 7,946 shares of Medpace stock in a transaction that occurred on Friday, March 29th. The shares were sold at an average price of $57.95, for a total value of $460,470.70. The disclosure for this sale can be found here. In the last three months, insiders have sold 44,983 shares of company stock worth $2,661,091. Corporate insiders own 24.20% of the company’s stock.

A number of research firms recently issued reports on MEDP. BidaskClub lowered Medpace from a “strong-buy” rating to a “buy” rating in a report on Friday, February 8th. TheStreet raised Medpace from a “c” rating to a “b-” rating in a report on Wednesday, April 10th. Wolfe Research began coverage on Medpace in a report on Tuesday, April 2nd. They set an “outperform” rating on the stock. Robert W. Baird raised their price target on Medpace from $57.00 to $62.00 and gave the stock a “neutral” rating in a report on Tuesday, April 30th. Finally, ValuEngine lowered Medpace from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $59.25.

NASDAQ MEDP opened at $53.98 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 0.69 and a current ratio of 0.69. Medpace Holdings Inc has a 52-week low of $41.27 and a 52-week high of $71.66. The stock has a market cap of $1.97 billion, a P/E ratio of 20.55, a P/E/G ratio of 1.67 and a beta of 1.51.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, April 29th. The company reported $0.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.60 by $0.04. Medpace had a return on equity of 17.16% and a net margin of 10.49%. The firm had revenue of $200.70 million for the quarter, compared to analyst estimates of $190.16 million. During the same quarter last year, the company posted $0.60 earnings per share. The business’s revenue was up 23.1% on a year-over-year basis. Analysts predict that Medpace Holdings Inc will post 2.64 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/fort-washington-investment-advisors-inc-oh-grows-holdings-in-medpace-holdings-inc-medp/3029056.html.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Recommended Story: Differences Between Momentum Investing and Long Term Investing

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings Inc (NASDAQ:MEDP).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.